Molecular characterization and management of secondary resistance to serial TRK inhibitors.
Michael J. Nathenson(Harvard University), George D. Demetri(Dana-Farber Cancer Institute), Monica M. Bertagnolli(National Institutes of Health), Karan Malik(Harvard University), Katherine A. Thornton(Memorial Sloan Kettering Cancer Center), Adrián Mariño‐Enríquez(Harvard University Press), Ewa Sicińska(Harvard University), Jia‐Ren Lin(Harvard University), Chandrajit P. Raut(Dana-Farber Cancer Institute), Timothy Hagan(Dana-Farber Cancer Institute), Otari Chipashvili(Harvard University), Ziming Du(Fuyang City People's Hospital), Sandro Santagata(Harvard University), Nora Ku(Loxo Oncology at Lilly (United States)), Barrett H. Childs(Florida Hospital Cancer Institute)
Cited by 1
Related Papers
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Copper induces cell death by targeting lipoylated TCA cycle proteins
|Science|2022|4.6k
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k